NCT04118062Completed
Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTOR)
Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. A Qualitative Cross-sectional Study of Professionals, Patients, Parents of Sick Children, and Expert Patients, in the Context of Triple Negative or Luminal B Breast Cancer, Metastatic Uveal Melanoma and Pediatric Cancers.
Source: ClinicalTrials.gov · Last updated 19 Sept 2025
Brief summary (registry, in English)
Resistance to treatment is one of the major themes in cancer research. Despite this, the definition and clinical implications of resistance to treatment remain under-explored, and patient-physician communication in this context still constitutes a challenge. When resistance to cancer treatments occurs, physicians not only have to explain to the patient the phenomenon of resistance, often based on complex results (biological results, genomic tests, imaging, etc.), but also need to offer alternative therapies, whilst fostering shared medical decision-making. These different tasks are particularly challenging for clinicians, especially since there are large individual differences at patient level. Indeed, each patient has his or her own unique information needs, capacity for understanding, and level of desire to participate in treatment decisions.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 128 (actual)
- First submitted
- 11 Sept 2019
- Start date
- 2 Feb 2021
- Primary completion date
- 26 May 2023
- Lead sponsor
- Institut Curie
- NCT number
- NCT04118062
What you commit to
- Study type: Interventional
- Participants enrolled: 128
- From 2 Feb 2021 to the primary completion date, 26 May 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients \& parents of a sick child:
- To have difficulties in understanding the French language.
- Have or have had cancer (criteria only for parents);
- Pregnant woman, likely to be pregnant or breastfeeding (criteria only for patients).
- Persons deprived of their liberty or under guardianship;
- Impossibility of study requirements respect for geographical, social or psychological reasons.
Other
- Expert patients:
- To have difficulties in understanding the French language ;
- Currently being undergoing anti-tumor treatment.
- Professionals:
- To have difficulties in understanding the French language ;
- Not to be confronted in professional practice with resistance to anti-tumor treatments.
Who the study is looking for
- Patients:
- To be 18 years of age or older ;
- To have metastatic uveal melanoma (MUM) or triple negative or luminal B breast cancer ;
- To have received the information that the disease is resistant to treatment ;
- To have read the information and signed the informed consent.
- Parents of a sick child:
- To be a parent (parental authority holder) of a child with cancer ;
- To have received the information that the child disease is resistant to treatment ;
- To have read the information and signed the informed consent.
- Expert patients:
- To be 18 years of age or older ;
- To have had cancer (regardless the cancer site) ;
- To participated to an expert patient training (fine knowledge of the illness, experience with the disease) ;
- To have read the information and signed the informed consent.
- Professionals:
- To be an oncologist (medical oncologist, surgeon, radiotherapist, supportive care specialist) and/or to be a researcher in oncology (doctor, biologist, geneticist ...) ;
- To have patients with a triple-negative or luminal B breast cancer or metastatic uveal melanoma which is resistant to anti-tumor treatments and/or to take part to a research on resistance to cancer treatment;
- To have read the information and signed the informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut Curie Coordinator of this site? Confirm its status | Paris | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.